The stock price of Unicycive Therapeutics Inc (NASDAQ: UNCY) has surged by 3.13 when compared to previous closing price of 0.63, but the company has seen a -5.00% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-13 that LOS ALTOS, Calif., March 13, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that it will present patient reported outcomes data from its pivotal UNI-OLC-201 clinical study characterizing the potential impact of oxylanthanum carbonate (OLC) on the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.
Is It Worth Investing in Unicycive Therapeutics Inc (NASDAQ: UNCY) Right Now?
The stock has a 36-month beta value of 2.14. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for UNCY is 86.07M, and at present, short sellers hold a 1.77% of that float. On March 28, 2025, the average trading volume of UNCY was 984.65K shares.
UNCY’s Market Performance
UNCY stock saw an increase of -5.00% in the past week, with a monthly gain of 14.44% and a quarterly increase of -3.61%. The volatility ratio for the week is 8.78%, and the volatility levels for the last 30 days are 9.60% for Unicycive Therapeutics Inc (UNCY). The simple moving average for the last 20 days is 8.25% for UNCY stock, with a simple moving average of 23.14% for the last 200 days.
Analysts’ Opinion of UNCY
Many brokerage firms have already submitted their reports for UNCY stocks, with Piper Sandler repeating the rating for UNCY by listing it as a “Overweight.” The predicted price for UNCY in the upcoming period, according to Piper Sandler is $9 based on the research report published on April 04, 2024 of the previous year 2024.
UNCY Trading at 9.45% from the 50-Day Moving Average
After a stumble in the market that brought UNCY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.62% of loss for the given period.
Volatility was left at 9.60%, however, over the last 30 days, the volatility rate increased by 8.78%, as shares surge +14.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.97% lower at present.
During the last 5 trading sessions, UNCY fell by -7.35%, which changed the moving average for the period of 200-days by -1.35% in comparison to the 20-day moving average, which settled at $0.5960. In addition, Unicycive Therapeutics Inc saw -18.66% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for UNCY
Current profitability levels for the company are sitting at:
- 107.63 for the present operating margin
- 2.35 for the gross margin
The net margin for Unicycive Therapeutics Inc stands at 106.74. The total capital return value is set at -1.04. Equity return is now at value -185.19, with -99.72 for asset returns.
Based on Unicycive Therapeutics Inc (UNCY), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -32.8. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -416.7.
Currently, EBITDA for the company is -30.18 million with net debt to EBITDA at 0.79. When we switch over and look at the enterprise to sales, we see a ratio of -124.91. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.61.
Conclusion
To sum up, Unicycive Therapeutics Inc (UNCY) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
